GO:0033137 negative regulation of peptidyl-serine phosphorylation: Signaling Brake, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033137 describes any biological process that stops, prevents, or reduces the phosphorylation of serine residues on target proteins.
• Serine phosphorylation is a central post-translational modification controlling signal transduction, cell cycle, and metabolism; its negative regulation is essential for preventing aberrant activation.
• Key negative regulators include protein phosphatases (e.g., PP2A, PP1) and kinases that phosphorylate inhibitory sites, such as eEF2K, which modulates translation elongation.
• Dysregulation of this process is implicated in cancer, where eEF2K overexpression correlates with poor survival and therapy resistance.
• MTF1, a metal-responsive transcription factor, can influence phosphorylation-dependent stress responses and cuproptosis, linking this GO term to cell death pathways.
• Neoadjuvant immunotherapy responses in esophageal squamous cell carcinoma involve modulation of phosphorylation signaling, highlighting clinical relevance.
Description
Phosphorylation of serine residues on proteins is one of the most pervasive post-translational modifications in eukaryotic cells, governing processes from signal transduction to cell division. The Gene Ontology term GO:0033137, negative regulation of peptidyl-serine phosphorylation, captures the biological processes that attenuate this modification. This term is critical for understanding how cells maintain signaling fidelity and prevent pathological hyperactivation. Research has shown that negative regulators of serine phosphorylation, such as protein phosphatases and inhibitory kinases, are frequently dysregulated in diseases including cancer and metabolic disorders. For example, eEF2K, a kinase that phosphorylates and inhibits eEF2, acts as a negative regulator of translation elongation and is associated with cancer survival and prognosis. Similarly, MTF1 has been linked to ROS-mediated cell death and cuproptosis, processes that intersect with phosphorylation signaling. In clinical settings, neoadjuvant immunotherapy for esophageal squamous cell carcinoma has been shown to modulate phosphorylation pathways, underscoring the therapeutic relevance of this regulatory process. Understanding GO:0033137 provides a framework for dissecting how cells balance kinase and phosphatase activities to maintain homeostasis.
negative regulation of peptidyl-serine phosphorylation At A Glance
| GO ID | GO:0033137 |
|---|---|
| GO term | negative regulation of peptidyl-serine phosphorylation |
| Ontology | biological_process |
| Synonym | None |
| Major function | Attenuation of serine phosphorylation on target proteins |
| Major regulators | Protein phosphatases (PP2A, PP1), inhibitory kinases (eEF2K), and scaffolding proteins |
| Associated diseases | Cancer, metabolic disorders, and stress-related pathologies |
| Research methods | Phosphoproteomics, CRISPR knockout, kinase/phosphatase assays |
What Is GO:0033137?
GO:0033137, negative regulation of peptidyl-serine phosphorylation, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the phosphorylation of peptidyl-serine. In simpler terms, it encompasses all molecular mechanisms that put the brakes on the addition of phosphate groups to serine residues in proteins. This regulation can occur through the action of phosphatases that remove phosphate groups, kinases that phosphorylate inhibitory sites to block subsequent phosphorylation, or scaffolding proteins that sequester substrates away from kinases. The term is a biological process and does not have synonyms in the QuickGO database.
Why Is negative regulation of peptidyl-serine phosphorylation Important in Cell Biology?
Negative regulation of peptidyl-serine phosphorylation is crucial for cellular homeostasis because unchecked serine phosphorylation can lead to aberrant activation of signaling pathways, uncontrolled cell proliferation, and disease. This process ensures that signals are transient and appropriately terminated, preventing chronic activation that contributes to oncogenesis and metabolic dysfunction. Moreover, it plays a key role in translational control, as seen with eEF2K, which negatively regulates eEF2 activity and is linked to cancer prognosis. Understanding this regulatory layer is essential for developing targeted therapies that modulate phosphorylation-dependent pathways.
• Prevents aberrant signaling by terminating kinase cascades.
• Controls translation elongation through eEF2K-mediated inhibition.
• Modulates stress responses and cell death pathways, including cuproptosis.
• Influences cancer prognosis and survival, as shown for eEF2K.
• Affects immunotherapy responses in esophageal squamous cell carcinoma.
• Regulates cell cycle progression by dephosphorylating key checkpoint proteins.
• Impacts metabolic homeostasis by modulating insulin signaling.
• Plays a role in neuronal function by regulating synaptic protein phosphorylation.
• Contributes to immune cell activation and cytokine production.
• Serves as a target for therapeutic intervention in kinase-driven diseases.
What Happens During negative regulation of peptidyl-serine phosphorylation?
Dephosphorylation by Protein Phosphatases
In simple terms: Enzymes called phosphatases remove phosphate groups from serine residues, effectively erasing the phosphorylation mark.
The most direct mechanism of negative regulation is the removal of phosphate groups from serine residues by protein phosphatases such as PP2A and PP1. These enzymes counteract the activity of serine/threonine kinases, ensuring that phosphorylation events are reversible and transient. For instance, PP2A dephosphorylates a wide range of substrates, including components of the MAPK and PI3K/AKT pathways, thereby dampening signal transduction. This dephosphorylation is critical for resetting signaling cascades after stimulation and preventing sustained activation that could lead to oncogenesis.
Inhibitory Phosphorylation of Kinases
In simple terms: Some kinases add phosphate groups to other kinases at specific sites to turn them off, a process called inhibitory phosphorylation.
Negative regulation can also occur through inhibitory phosphorylation, where a kinase phosphorylates a serine or threonine residue on another kinase, rendering it inactive. A classic example is eEF2K, which phosphorylates eEF2 at Thr56 and Thr58, inhibiting translation elongation. Although eEF2K itself is a kinase, its activity is subject to negative regulation by upstream kinases such as AMPK and p70S6K, which phosphorylate inhibitory sites. This layered regulation ensures that translation is halted under stress conditions but resumes when favorable conditions return.
Sequestration and Scaffolding
In simple terms: Scaffolding proteins can hold kinases and substrates apart or bring phosphatases close, preventing or reversing phosphorylation.
Scaffolding proteins and subcellular localization play important roles in negative regulation. For example, AKAPs (A-kinase anchoring proteins) can tether protein kinase A and phosphatases to specific compartments, spatially restricting phosphorylation events. Similarly, 14-3-3 proteins bind to phosphorylated serine residues and can mask them from kinases or phosphatases, effectively sequestering the modification. These mechanisms add another layer of control, ensuring that phosphorylation occurs only at the right place and time.
Feedback Loops and Crosstalk
In simple terms: Signaling pathways often have built-in feedback loops where the output of a pathway inhibits an upstream component, reducing serine phosphorylation.
Negative feedback loops are a common theme in serine phosphorylation regulation. For instance, activation of the mTOR pathway leads to phosphorylation of S6K, which in turn phosphorylates and inhibits IRS-1, dampening insulin signaling. Similarly, ERK-mediated phosphorylation of SOS can disrupt the RAS-ERK complex, attenuating the pathway. These feedback mechanisms rely on serine phosphorylation events that ultimately reduce the frequency or extent of further phosphorylation, aligning with the definition of GO:0033137.
Key Genes Involved in GO:0033137 negative regulation of peptidyl-serine phosphorylation
The following genes and proteins are key players in the negative regulation of peptidyl-serine phosphorylation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPP2CA | Catalytic subunit of PP2A, a major serine/threonine phosphatase | Tumor suppressor, dephosphorylates oncogenic kinases |
| PPP1CA | Catalytic subunit of PP1, dephosphorylates serine residues | Regulates cell cycle and glycogen metabolism |
| EEF2K | Kinase that phosphorylates eEF2, inhibiting translation | Associated with cancer survival and prognosis |
| MTF1 | Metal-responsive transcription factor, modulates stress responses | Linked to cuproptosis and ROS-mediated cell death |
| AKT1 | Serine/threonine kinase, phosphorylates many substrates | Negatively regulated by phosphatases; oncogene |
| MAPK1 | ERK2, serine/threonine kinase in MAPK pathway | Feedback dephosphorylation by phosphatases |
| CDK1 | Cyclin-dependent kinase 1, regulates cell cycle | Inhibited by phosphorylation on inhibitory sites |
| GSK3B | Glycogen synthase kinase 3 beta, serine/threonine kinase | Negatively regulated by AKT-mediated phosphorylation |
| PDPK1 | PDK1, activates AKT by phosphorylation | Dephosphorylated by PP2A |
| RPS6KB1 | S6K1, phosphorylates ribosomal protein S6 | Negatively regulates IRS-1 via serine phosphorylation |
| IRS1 | Insulin receptor substrate 1 | Inhibited by serine phosphorylation, feedback loop |
| PPP2R1A | Scaffold subunit of PP2A | Mutations in cancer; regulates phosphatase activity |
| PPP2R2A | Regulatory subunit of PP2A | Determines substrate specificity |
| PPM1A | Protein phosphatase 1A, dephosphorylates serine residues | Regulates stress responses |
| PPM1B | Protein phosphatase 1B | Involved in cell cycle regulation |
| DUSP1 | Dual-specificity phosphatase 1 | Dephosphorylates MAPK on serine/threonine |
| DUSP6 | Dual-specificity phosphatase 6 | Negative regulator of ERK signaling |
How Is negative regulation of peptidyl-serine phosphorylation Regulated?
The process of negative regulation of peptidyl-serine phosphorylation is itself tightly regulated. Upstream signals such as growth factors, stress, and nutrients can activate or inhibit phosphatases and inhibitory kinases. For example, mTORC1 phosphorylates and inhibits PP2A, thereby promoting phosphorylation. Conversely, AMPK activates PP2A and eEF2K under energy stress, reducing translation and serine phosphorylation of specific substrates. Additionally, reactive oxygen species can oxidize phosphatase active sites, transiently inhibiting their activity and shifting the balance toward phosphorylation. These regulatory layers ensure that the negative regulation of serine phosphorylation is context-dependent and reversible.
negative regulation of peptidyl-serine phosphorylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EEF2K | Cancer survival and prognosis | Knockout in cancer cell lines, xenograft models |
| PPP2CA | Tumor suppression, insulin resistance | Conditional knockout mice, CRISPR point mutants |
| MTF1 | Cuproptosis, ROS-mediated cell death | Overexpression and knockout in hepatocellular carcinoma |
| IRS1 | Type 2 diabetes, insulin resistance | Point mutation knock-in mice |
| MAPT (Tau) | Alzheimer's disease | Phospho-mutant knock-in mice |
Cancer
Dysregulation of serine phosphorylation is a hallmark of cancer. Overexpression of eEF2K, a negative regulator of translation, is associated with poor survival in multiple cancers, as it promotes adaptation to stress and resistance to apoptosis. Loss of PP2A function, due to mutations or reduced expression, leads to hyperphosphorylation of oncogenic kinases such as AKT and ERK, driving tumorigenesis. Targeting the negative regulators of serine phosphorylation is therefore a promising therapeutic strategy.
Metabolic Disorders
Serine phosphorylation plays a critical role in insulin signaling. Negative regulation of IRS-1 phosphorylation by phosphatases is essential for maintaining insulin sensitivity. In obesity and type 2 diabetes, chronic activation of kinases such as S6K1 leads to inhibitory phosphorylation of IRS-1, contributing to insulin resistance. Modulating the negative regulators could restore metabolic balance.
Neurodegeneration
Aberrant serine phosphorylation of tau protein is a key feature of Alzheimer's disease. Negative regulation of tau phosphorylation by phosphatases such as PP2A is impaired in Alzheimer's brains, leading to neurofibrillary tangles. Enhancing phosphatase activity is being explored as a therapeutic approach.
Cuproptosis and Metal Stress
MTF1, a metal-responsive transcription factor, influences the expression of genes involved in copper homeostasis and cell death. Its role in cuproptosis, a copper-dependent cell death pathway, intersects with phosphorylation signaling, as MTF1 activity can be modulated by phosphorylation. This links GO:0033137 to metal-induced stress responses.
From negative regulation of peptidyl-serine phosphorylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a phosphatase increase serine phosphorylation? | CRISPR knockout of PPP2CA in cell lines |
| Does a specific phosphorylation site regulate protein function? | Point mutation (Ser to Ala) knock-in |
| Can a kinase inhibitor block negative regulation? | Overexpression of eEF2K followed by inhibitor treatment |
| How does MTF1 modulate cuproptosis? | MTF1 overexpression and knockout in liver cancer cells |
| What is the role of PP2A in insulin signaling? | Liver-specific PP2A knockout mice |
| Does neoadjuvant immunotherapy alter phosphorylation? | Patient-derived xenografts treated with sintilimab |
How to Study the negative regulation of peptidyl-serine phosphorylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Global serine phosphorylation sites | Discovering negative regulators |
| CRISPR knockout screen | Genes affecting phosphorylation | Identifying phosphatases |
| Western blot | Specific phospho-serine levels | Validating signaling changes |
| In vitro phosphatase assay | Enzyme activity | Testing inhibitors |
| Immunoprecipitation | Protein-protein interactions | Studying scaffold complexes |
| Flow cytometry | Phospho-protein levels in single cells | Analyzing heterogeneous responses |
| RNA-seq | Transcriptional changes | Linking phosphorylation to gene expression |
Phosphoproteomics
Mass spectrometry-based phosphoproteomics allows global profiling of serine phosphorylation sites. By comparing control and treated samples, researchers can identify sites whose phosphorylation is negatively regulated. This method is powerful for discovering novel substrates of phosphatases and kinases.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes whose loss alters serine phosphorylation. For example, knocking out phosphatases may increase phosphorylation of downstream targets, revealing negative regulators. This approach is unbiased and scalable.
Western Blotting with Phospho-specific Antibodies
Immunoblotting with antibodies that recognize specific phosphorylated serine residues is a standard method to assess changes in phosphorylation. It is used to validate findings from high-throughput screens and to monitor signaling dynamics.
In Vitro Kinase and Phosphatase Assays
Recombinant kinases and phosphatases can be used in vitro to directly test their activity on substrate peptides. These assays provide mechanistic insights into the regulation of serine phosphorylation and are useful for drug discovery.
How CRISPR Can Be Used to Study GO:0033137 negative regulation of peptidyl-serine phosphorylation
Knockout
CRISPR knockout of genes encoding negative regulators, such as PPP2CA or EEF2K, can lead to increased serine phosphorylation of downstream targets. This approach is used to study the loss-of-function phenotypes and to validate the role of specific phosphatases in signaling pathways.
Point Mutation
Introducing point mutations that convert serine to alanine (phospho-deficient) or to aspartate (phospho-mimetic) in substrate proteins allows researchers to dissect the functional consequences of individual phosphorylation sites. This is particularly useful for studying feedback loops.
Knock-in
Knock-in of tagged versions of phosphatases or kinases (e.g., GFP or HA tags) enables live-cell imaging and proteomic analysis of these regulators. It also allows for the study of their localization and dynamics under different conditions.
Overexpression
Overexpression of negative regulators, such as eEF2K or PP2A subunits, can suppress serine phosphorylation and inhibit downstream signaling. This approach is used to test the sufficiency of a regulator in blocking a pathway and to model therapeutic interventions.
How EDITGENE Supports negative regulation of peptidyl-serine phosphorylation Research
Researchers studying negative regulation of peptidyl-serine phosphorylation-related genes often need to determine whether a candidate gene is causally involved in modulating phosphorylation events. This requires precise genetic manipulation, which can be achieved through CRISPR-based models. EDITGENE provides a comprehensive suite of services to support such investigations, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of peptidyl-serine phosphorylation research.
Frequently Asked Questions About negative regulation of peptidyl-serine phosphorylation
What is negative regulation of peptidyl-serine phosphorylation?
It is any process that stops, prevents, or reduces the phosphorylation of serine residues on proteins, as defined by GO:0033137.
What genes are involved in negative regulation of peptidyl-serine phosphorylation?
Key genes include PPP2CA, PPP1CA, EEF2K, MTF1, and DUSP1, among others.
How does eEF2K negatively regulate serine phosphorylation?
eEF2K phosphorylates eEF2 at specific serine/threonine residues, inhibiting translation elongation, and its activity is itself negatively regulated by upstream kinases.
What diseases are associated with dysregulated serine phosphorylation?
Cancer, metabolic disorders like type 2 diabetes, and neurodegenerative diseases such as Alzheimer's are linked to aberrant serine phosphorylation.
What methods are used to study negative regulation of peptidyl-serine phosphorylation?
Phosphoproteomics, CRISPR screens, Western blotting, and in vitro phosphatase assays are commonly used.
Can CRISPR be used to study this process?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the regulators and substrates.
What is the role of MTF1 in this context?
MTF1 is a metal-responsive transcription factor that influences cuproptosis and ROS-mediated cell death, processes that intersect with phosphorylation signaling.
How does neoadjuvant immunotherapy affect serine phosphorylation?
In esophageal squamous cell carcinoma, neoadjuvant sintilimab combined with chemotherapy modulates phosphorylation pathways, as shown in clinical studies.
What are the major phosphatases involved?
PP2A and PP1 are the primary serine/threonine phosphatases that remove phosphate groups from serine residues.
Why is negative regulation important for cancer therapy?
It prevents hyperactivation of oncogenic kinases; loss of negative regulators like PP2A leads to tumorigenesis, making them therapeutic targets.
Conclusion
GO:0033137, negative regulation of peptidyl-serine phosphorylation, is a fundamental biological process that ensures signaling fidelity and prevents disease. Its dysregulation is implicated in cancer, metabolic disorders, and neurodegeneration, making it a rich area for research. Advances in CRISPR technology and phosphoproteomics are enabling precise dissection of the regulators and substrates involved. EDITGENE provides the tools and services to accelerate these discoveries, from custom knockout models to bioinformatics support.
References
- 1. Wang N et al.. 2024. eEF2K as an important kinase associated with cancer survival and prognosis.. Sci Rep 14(1):29284 PMID: 39592671
- 2. Song L et al.. 2023. The biological significance of cuproptosis-key gene MTF1 in pan-cancer and its inhibitory effects on ROS-mediated cell death of liver hepatocellular carcinoma.. Discov Oncol 14(1):113 PMID: 37380924
- 3. Wu H et al.. 2026. Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced, resectable esophageal squamous cell carcinoma: clinical study and mechanistic exploration.. NPJ Precis Oncol 10(1) PMID: 41548037
